Hair Cloning and Follicle Neogenesis: Where the Science Really Is in 2026

A friend texted me a screenshot last spring. The headline said “hair cloning breakthrough could end baldness.” He’d seen three versions of the same claim that month, from three different outlets, all citing different companies. None of the articles explained what “cloning” actually meant, or whether the follicles in the photos were genuinely new or just reactivated ones. That confusion is not accidental. It’s baked into the way these stories get written, and it costs people real money in wrong treatment choices.

Related on the Blueprint: PP405: Is the Baldness Cure Real and JXL069 for Hair Loss.

So let me draw a clean line between two things the internet keeps collapsing into one word.

Reactivation versus true neogenesis: they are not the same thing

Your scalp in male-pattern hair loss does not immediately become a barren wasteland. The process is gradual. Follicles go through cycles of miniaturization: each new hair shaft comes back thinner, shorter, and lighter than the last. Deep in those follicles, stem cell populations often persist even when the follicle has effectively stopped producing visible hair. “Dormant” is the right word for many of them. They’re still there. They’ve just stopped cycling.

Follicle reactivation means waking those dormant units back up. You’re working with living biology that’s already in the scalp. It’s a restoration job.

True hair cloning, or follicle neogenesis, is something else entirely. It means generating brand-new follicles from cultured cells, building structures from scratch that were never there or that have been completely lost. A slick-bald scalp where follicles have permanently miniaturized and the dermal papilla has been depleted can’t be helped by reactivation because there’s nothing left to reactivate. That is where neogenesis would matter. And that is precisely why it’s so hard.

Most “cure” headlines blur these two concepts into a single exciting noun. That one conflation has probably caused more misinformed expectations than any other single thing in this field.

Why neogenesis is genuinely hard

Mouse models gave researchers an early hint that new follicles could form. Wnt pathway activation in wound healing was shown to trigger follicle neogenesis in mice, a genuinely exciting finding.^[2] The leap from “works in mice” to “works in humans” has, so far, not happened. Human skin is thicker, the dermal-epidermal crosstalk is more complex, and the regulatory signals that tell a forming follicle which direction to grow and when to start cycling are still not fully mapped.

Early attempts at cell-based approaches produced disorganized cysts rather than proper cycling follicles. The cells would proliferate. They just wouldn’t self-assemble into the right architecture. Getting orientation right, making a follicle that points the correct direction and produces a terminal hair shaft rather than a downy vellus fiber, remains an open bioengineering problem.

Stemson Therapeutics, which had attracted significant attention as one of the most serious cloning-focused startups, shut down. HairClone, a UK company that has been working on banked papilla cell therapies, has not produced major clinical updates. The honest consensus in the field is that a commercially available neogenesis treatment is a 2030s story at the very earliest, and some researchers would put it later than that.

PP405: the most interesting near-term thing, properly labeled

This is where I want to spend some time, because PP405 from Pelage Pharmaceuticals is genuinely exciting. But I want to be clear about what it is, because the distinction matters enormously for who it might actually help.

PP405 is a topical small molecule. It works by targeting a metabolic switch in follicle stem cells, specifically a mitochondrial pathway that governs whether a stem cell enters an active or quiescent state.^[3] By flipping that switch, PP405 appears to pull dormant follicle stem cells back into an active cycling state. New terminal hairs have been observed growing from previously quiescent follicular units in the trials. That’s real. That’s measurable.

But say it clearly: this is reactivation, not cloning. PP405 cannot conjure a follicle that is no longer there. If you’ve lost follicle tissue entirely at a given site, there’s nothing left for PP405 to wake up.

Phase 2a results were presented at the AAD 2026 annual meeting.^[1] The drug was well tolerated. Hair density gains were measurable across the group. Among men with more advanced thinning, roughly 31 percent saw greater than 20 percent improvement in hair density.^[2] That’s a meaningful signal. Late-stage studies are expected to begin in 2026, which means we could have a clearer efficacy picture within a few years.^[4]

Understanding the 31% number honestly

Thirty-one percent is not a small effect in a hard-to-treat population. Men with more advanced thinning are exactly the group where the existing toolkit (primarily DHT-blockers) has the most limited upside, because follicle miniaturization is further along. Seeing terminal hair grow from previously dormant units at that stage is a real signal.

But 31% also means 69% of that same group did not cross the 20% density threshold. We don’t yet know the full breakdown of why. How many follicle stem cells were still viable? What was the thinning stage distribution within “more advanced”? Were there responder characteristics that could predict who benefits? Those are the questions late-stage trials will need to answer, and they’re not answered yet.

I’ll also note the limitation I can’t ignore: Phase 2a data is signal-finding. The sample sizes are smaller, there’s no long-term follow-up yet, and the responder definition of “greater than 20% density improvement” needs to be validated against what patients actually perceive as meaningful change. This is promising. It is not proven.

My analogy for the whole situation

Think of a dormant follicle like a car with a dead battery. It’s sitting in your driveway, structurally intact, with all its parts still there. PP405 is a jump-start. Given enough charge, the engine turns over, the car drives. But if the engine block itself has been removed, a jump-start does nothing. True cloning would be machining a new engine from raw materials and installing it. We know, conceptually, how engines work. We can even build simple ones. But manufacturing them reliably at scale, tuning them to each driver’s car, making them run properly after installation: we’re nowhere near the mass-production stage. PP405 is a real jump-start technology. Cloning is a future-decade engine factory.

Where this leaves someone with active hair loss right now

The honest answer depends heavily on how far along you are.

If you’re in early-to-moderate thinning and you still have significant follicle tissue, you have the most to gain from any reactivation approach, including what PP405 might offer once approved, plus the existing options that are already available. That’s the population where maintenance and reactivation matter most.

If you’re looking at advanced, diffuse loss with significant follicle depletion, the realistic honest picture is that reactivation therapies, including PP405, are likely to show more modest returns. That’s not pessimism. It’s biology. The population where true neogenesis would be transformative is exactly that population, and that technology isn’t here yet.

The practical implication is this: act earlier, not later. Every year of delay in a responsive window is a year of irreversible miniaturization at some follicles. The treatments that exist and the treatments coming through trials work better when there’s more viable biology to work with. That’s not a sales pitch. It’s just the mechanism.

Comparing where the major approaches stand

What to watch for in the next two years

The Phase 3 data for PP405 is the single most important signal coming. If the late-stage trial holds the Phase 2a effect size across a larger population, and if the responder profile gets better defined, that’s a genuinely new tool. The AAD presentation in 2026 drew significant clinical attention for a reason.^[1]

On the neogenesis side, watch for preclinical publications on organoid models. Several academic groups are working on follicle organoids that self-assemble in vitro into structures resembling real follicles. That’s basic science, years from anything clinical, but it’s where the foundational problem-solving is happening.

The key question I’d want answered before getting excited about any cloning claim: did the new follicle cycle? Producing a hair shaft once is one thing. A follicle that enters and exits anagen repeatedly is a different, much harder thing. Without cycling, it’s a cyst, not a follicle.

More of my analysis of hair biology and the ongoing research landscape is at philippeb.pro, including my openly available review of androgenetic alopecia treatment mechanisms.